Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...

Flu is a viral infection affecting the nose, throat and lungs, mostly during the winter months. It is far worse than an ...

• Respiratory syncytial virus (RSV) infections are above the alert level. • Seasonal influenza (flu) infections are well ...

The child, a resident of the Gota area, is receiving treatment at a trust-run hospital and is in stable condition ...

The child from the city’s Gota area is currently being treated at a trust-run hospital and his condition is stable, said ...

COVID-19 remains a critical health threat in the United States, accounting for three out of five respiratory illnesses among veterans during the recent cold and flu season ...

The transaction would allow Sanofi to solely focus on its more lucrative, drugs and vaccines business. The company's research-and-development spending increased 24% on-year in the last quarter in an ...